Potent human fatty acid synthase (hFASN) inhibitor (IC50 = 7.7 nM); inhibits hFAS β-ketoacyl reductase activity. Inhibits lipid synthesis and attenuates proliferation of A549 non-small-cell lung cancer cells (EC50 = 15 nM) in vitro.
Sold for research purposes under agreement from GlaxoSmithKline
|Storage||Store at +4°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 428.48. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.33 mL||11.67 mL||23.34 mL|
|5 mM||0.47 mL||2.33 mL||4.67 mL|
|10 mM||0.23 mL||1.17 mL||2.33 mL|
|50 mM||0.05 mL||0.23 mL||0.47 mL|
The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.
References are publications that support the products' biological activity.
Hardwicke et al (2014) A human fatty acid synthase inhibitor binds β-ketoacyl reductase in the keto-substrate site. Nat.Chem.Biol. 10 774 PMID: 25086508
If you know of a relevant reference for GSK 2194069, please let us know.
View Related Products by Product Action
Keywords: GSK2194069 fatty acid synthases hFAS beta-ketoacyl reductases b-ketoacyl β-ketoacyl lipid synthesis inhibitors inhibits Fatty Acid Synthase
Citations for GSK 2194069
Citations are publications that use Tocris products.
Currently there are no citations for GSK 2194069. Do you know of a great paper that uses GSK 2194069 from Tocris? If so please let us know.